Johannes Krieger, Fiona J. Sorrell, Ansgar A. Wegener, Birgitta Leuthner, Fouzia Machrouhi‐Porcher, Martin Hecht, Eva M. Leibrock, Juliane E. Müller, Jonathan Eisert, Ingo V. Hartung and Sarah Schlesiger

ChemMedChem, 2023, 18
DOI: 10.1002/cmdc.202200615

A ubiquitination-mediated degradation system to target 14-3-3-binding phosphoproteins

Zhaokai Li, Xiaoqiang Huang, Mohan Li, Y. Eugene Chen, Zhong Wang and Liu Liu

Heliyon, 2023, 9, e16318
DOI: 10.1016/j.heliyon.2023.e16318

Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs)

Amr Abbas and Fei Ye

International Journal of Biological Macromolecules, 2024, 277, 134293
DOI: 10.1016/j.ijbiomac.2024.134293

Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors

Heli Fan, Zhili Zhou, Dehao Yu, Jing Sun, Luo Wang, Yuanyuan Jia, Junyu Tian, Wenyi Mi and Huabing Sun

Bioorganic Chemistry, 2023, 140, 106793
DOI: 10.1016/j.bioorg.2023.106793

Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review

André T. S. Vicente and Jorge A.R. Salvador

Expert Opinion on Therapeutic Patents, 2023, 33, 397
DOI: 10.1080/13543776.2023.2240025

Development of 2-Aminoadenine-Based Proteolysis-Targeting Chimeras (PROTACs) as Novel Potent Degraders of Monopolar Spindle 1 and Aurora Kinases

Eleni Sflakidou, Bikash Adhikari, Christos Siokatas, Elmar Wolf and Vasiliki Sarli

ACS Pharmacol. Transl. Sci., 2024, 7, 3488
DOI: 10.1021/acsptsci.4c00405

Non-Markovian Dynamic Models Identify Non-Canonical KRAS-VHL Encounter Complex Conformations for Novel PROTAC Design

Yunrui Qiu, Rafal P. Wiewiora, Jesus A. Izaguirre, Huafeng Xu, Woody Sherman, Weiping Tang and Xuhui Huang

JACS Au, 2024, 4, 3857
DOI: 10.1021/jacsau.4c00503

Synergistic Effects of Combined PROTAC-based EZH2 Degrader and METTL3 Inhibitor in Burkitt’s Lymphoma

Minseo YU, Ra Eun KIM, Yurim JEONG, Hyewon JANG, Se Been KIM and Jung-Yeon LIM

Korean J Clin Lab Sci, 2024, 56, 198
DOI: 10.15324/kjcls.2024.56.3.198

Advancing cancer immunotherapy: Small-Molecule, biomacromolecular, and nanoscale PROTACs targeting PD-L1 for degradation

Yang Meng, Yujing Zhang, Wanpeng Yu, Dongming Xing and Chao Wang

Materials Today Advances, 2025, 27, 100606
DOI: 10.1016/j.mtadv.2025.100606

Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader

Mingxing Teng, Jie Jiang, Eric S. Wang, Qixiang Geng, Sean T. Toenjes, Katherine A. Donovan, Nada Mageed, Hong Yue, Radosław P. Nowak, Jinhua Wang, Theresa D. Manz, Eric S. Fischer, Lewis C. Cantley and Nathanael S. Gray

Angewandte Chemie, 2023, 135
DOI: 10.1002/ange.202302364

Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α

Mónica Cubillos-Rojas, Guillem Loren, Yusuf Z. Hakim, Xavier Verdaguer, Antoni Riera and Angel R. Nebreda

Cancers, 2023, 15, 611
DOI: 10.3390/cancers15030611

A Gold-PROTAC Degrades the Oncogenic Tyrosine Kinase MERTK: Insights into the Degradome from a Steady-State System

Sophie R. Thomas, Thomas Iellici, Mihyun Park, Elisabeth Klaus, Andrea Bileck, Christopher Gerner, Samuel M. Meier-Menches and Angela Casini

ACS Chem. Biol., 2026, 21, 170
DOI: 10.1021/acschembio.5c00860

PROTACs: A novel strategy for cancer drug discovery and development

Xin Han and Yi Sun

MedComm, 2023, 4
DOI: 10.1002/mco2.290

Discovery of novel benzosultam CRBN ligands

Hoyeong Park, Santosh Shivanand Raikar, Yonghyo Kim, Chong Hak Chae, Yong‐Hee Cho and Pilho Kim

Bulletin Korean Chem Soc, 2025, 46, 48
DOI: 10.1002/bkcs.12921

Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines

Karina Chan, Preethi Soundarya Sathyamurthi, Markus A. Queisser, Michael Mullin, Harry Shrives, Diane M. Coe and Glenn A. Burley

Bioconjugate Chem., 2023, 34, 2049
DOI: 10.1021/acs.bioconjchem.3c00366

Application of proteolysis targeting chimeric (PROTAC) technology in protein regulation and drug development

Yiting He, Tianzuo Liao, Xuan'er Wang, Qian Xiao, Hongmei Wang, Rui He, Chenyu Zhao, Xinmiao Tian, Qinghua Gao and Liying Hao

Bioorganic Chemistry, 2025, 164, 108846
DOI: 10.1016/j.bioorg.2025.108846

Rapid synthesis of proteolysis-targeting chimeras by consecutive click assembly

Yuri Taninaga, Gaku Orimoto, Maho Miyamoto, Kaho Yamada, Hidetomo Yokoo, Yosuke Demizu and Suguru Yoshida

Bulletin of the Chemical Society of Japan, 2025, 98
DOI: 10.1093/bulcsj/uoaf115

Precision-engineered PROTACs minimize off-tissue effects in cancer therapy

Jianghua Shi, Luo Wang, Xuanwei Zeng, Chengzhi Xie, Zhaowei Meng, Anahit Campbell, Lulu Wang, Heli Fan and Huabing Sun

Front. Mol. Biosci., 2024, 11
DOI: 10.3389/fmolb.2024.1505255

A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

Aina Urbina, Alex J. Hallatt, Jack Robertson and Alessio Ciulli

Expert Opinion on Therapeutic Patents, 2025, 35, 197
DOI: 10.1080/13543776.2024.2446232

Targeted protein degradation: therapeutic potential and challenges of PROTACs and molecular glues

Sun Kim and Eui-Bae Jeung

J Biomed Transl Res, 2025, 26, 21
DOI: 10.12729/jbtr.2025.26.2.21

Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease

Qiuzhi Zhou, Weixia Wang and Chunchu Deng

Mol Neurobiol, 2025, 62, 9686
DOI: 10.1007/s12035-025-04838-0

Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader

Mingxing Teng, Jie Jiang, Eric S. Wang, Qixiang Geng, Sean T. Toenjes, Katherine A. Donovan, Nada Mageed, Hong Yue, Radosław P. Nowak, Jinhua Wang, Theresa D. Manz, Eric S. Fischer, Lewis C. Cantley and Nathanael S. Gray

Angew Chem Int Ed, 2023, 62
DOI: 10.1002/anie.202302364

Targeting BRD4 in cancer therapy: From inhibitors and degraders to novel combination strategies and resistance mechanisms

Xi-Bo Wang, Rui-Jing Meng, Wen-Jin Cao, Lei Cheng, Junmin Zhang and Shi-Wu Chen

Bioorganic & Medicinal Chemistry, 2026, 132, 118473
DOI: 10.1016/j.bmc.2025.118473

Harnessing the E3 ligase SPOP for targeted degradation of the NUP98::KDM5A fusion oncoprotein

Ecem Kirkiz, Gabriel Kaufmann, Simone Bergqvist, Pablo Fernández-Pernas, Thomas Eder, Laura Quell, Melanie Allram, Gabriele Manhart, Wencke Walter, Torsten Haferlach and Florian Grebien

Cell Reports, 2025, 44, 116602
DOI: 10.1016/j.celrep.2025.116602

Nuclear Magnetic Resonance‐based fragment screen of the E3 ligase Fem‐1 homolog B

Jade M. Katinas, Kangsa Amporndanai, Ashley J. Taylor, Kristie L. Rose, Peter C. Gareiss, Roberto A. Crespo, Jason Phan, Alex G. Waterson and Stephen W. Fesik

Protein Science, 2025, 34
DOI: 10.1002/pro.70365

Enhancing Solubility in VHL-Based PROTACs: Optimized USP7 Degraders for Improved Developability

Sophie Wittenburg, Maximilian R. Zuleeg, Kirsten Peter, Patricia Lemnitzer, Rabea Voget, Aleša Bricelj, Martina Gobec, Nele Dierlamm, Michael B. Braun, Thomas M. Geiger, Christopher Heim, Alicia Stakemeier, Karl G. Wagner, Radosław P. Nowak, Marcus D. Hartmann, Izidor Sosič, Michael Gütschow, Jan Krönke and Christian Steinebach

J. Med. Chem., 2025, 68, 15711
DOI: 10.1021/acs.jmedchem.5c00718

FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives

Heba M. Hesham, Eman M.E. Dokla, Eman Z. Elrazaz, Deena S. Lasheen and Dalal A. Abou El Ella

European Journal of Medicinal Chemistry, 2024, 277, 116717
DOI: 10.1016/j.ejmech.2024.116717

Construction of novel magnetic systems for cancer immunotherapy via cancer-immunity cycle circuits

Linghong Huang, Quan Zhang, Jun Long, Zonghua Liu and Xinyuan Sun

Journal of Controlled Release, 2025, 378, 38
DOI: 10.1016/j.jconrel.2024.12.009

A double-edged sword of neo-substrate degradation in PROTACs

Zihan Song, Chengze Duan, Mingfei Wu, Zunyuan Wang, Youlu Pan, Chixiao Zhang, Wenhai Huang and Shenxin Zeng

European Journal of Medicinal Chemistry, 2026, 301, 118253
DOI: 10.1016/j.ejmech.2025.118253

A patent review on hypoxia-inducible factor (HIF) modulators (2021–2023)

Jiaming Liu, Yinli Gao and Xiaojin Zhang

Expert Opinion on Therapeutic Patents, 2024, 34, 651
DOI: 10.1080/13543776.2024.2368739

Auto-RapTAC: A Versatile and Sustainable Platform for the Automated Rapid Synthesis and Evaluation of PROTAC

Jiexuan Chen, Mingfei Wu, Jun Mo, Ju Hong, Wei Wang, Yuheng Jin, Xinfei Mao, Xueyan Liao, Kailin Li, Xiaoli Yu, Sikang Chen, Shenxin Zeng, Wenhai Huang, Hongxia Xu, Jian Wu, Ji Cao, Yubo Zhou, Meidan Ying, Chengliang Zhu, Qiaojun He, Bo Zhang, Nengming Lin, Xiaowu Dong and Jinxin Che

J. Med. Chem., 2025, 68, 8010
DOI: 10.1021/acs.jmedchem.4c02438

Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress

Jing Chen, Disheng Feng, Rui Zhu, Hua Li and Lixia Chen

Redox Biology, 2025, 85, 103781
DOI: 10.1016/j.redox.2025.103781

Advances in light-controllable PROTACs: Design strategies, therapeutic applications and current challenges

Ji Wu, Zi-Yue Wang, Shi-Xuan Tan, Ting-Yu Li, Bing-Bing Chen, Qi-Qi Chen, Hao Li, Jin-Bo Niu, Xiang-Jing Fu, Jian Song and Sai-Yang Zhang

Bioorganic Chemistry, 2026, 169, 109380
DOI: 10.1016/j.bioorg.2025.109380

Discovery of a Natural Ent-Kaurene Diterpenoid Oridonin as an E3 Ligase Recruiter for PROTACs

Jie Huang, Xuekun Fu, Fang Qiu, Zhijian Liang, Chunhao Cao, Zhuqian Wang, Hongzhen Chen, Siran Yue, Duoli Xie, Yiying Liang, Aiping Lu and Chao Liang

J. Am. Chem. Soc., 2025, 147, 1920
DOI: 10.1021/jacs.4c14650

Discovery of potent and selective PROTACs for the protein kinase LZK for the treatment of head and neck cancer

Meghri Katerji, Knickole L. Bergman, Eric Lindberg, Maxine R. Rubin, Marwa Afifi, Amy L. Funk, Carolyn C. Woodroofe, Katherine Nyswaner, Kamila Karpińska, Remigiusz Serwa, Steven D. Cappell, Anna Marusiak, Rolf E. Swenson and John F. Brognard

Journal of Biological Chemistry, 2025, 301, 108452
DOI: 10.1016/j.jbc.2025.108452

Ubiquitin recruiting chimera: more than just a PROTAC

Tatyana A. Grigoreva, Daria S. Novikova, Gerry Melino, Nick A. Barlev and Vyacheslav G. Tribulovich

Biol Direct, 2024, 19
DOI: 10.1186/s13062-024-00497-8

Cysteine-reactive covalent chloro-N-acetamide ligands induce ferroptosis mediated cell death

Gina Gotthardt, Janik Weckesser, Georg Tascher, Sara Barros da Gama, Hannah J Uckelmann, Shibo Sun, Martin P Schwalm, Thorsten Mosler, Giulio Ferrario, José Pedro Friedmann Angeli, Christian Münch, Stefan Knapp and Stefan Müller

EMBO Rep, 2025, 26, 5501
DOI: 10.1038/s44319-025-00593-4

Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy

Zheng Li, Guodong Ren, Xuewei Wang, Xiaowan Li, Lingwen Ding, Jianwei Zhu, Yajie Zhang, Chengwu Zhang, Jianhua Zou and Xiaoyuan Chen

Biomaterials, 2025, 322, 123387
DOI: 10.1016/j.biomaterials.2025.123387

Advances in molecular glues: exploring chemical space and design principles for targeted protein degradation

S Hemant Kumar, Muthukumaran Venkatachalapathy, Ramesh Sistla and Vasanthanathan Poongavanam

Drug Discovery Today, 2024, 29, 104205
DOI: 10.1016/j.drudis.2024.104205

Identification of novel 7-hydroxycoumarin derivatives as ELOC binders with potential to modulate CRL2 complex formation

Yonghyeok Kim, Seon Jeong Baek, Eun-Kyung Yoon, Minhee Choi, Jung-Hoon Kim, Kyungtae Kim, Chi Hoon Park and Byung Il Lee

Sci Rep, 2025, 15
DOI: 10.1038/s41598-025-88166-2

Computational Modeling of PROTAC Ternary Complexes as Ensembles Using SILCS-xTAC

Erik B. Nordquist, Mingtian Zhao, Wenbo Yu and Alexander D. MacKerell Jr

J. Chem. Inf. Model., 2026, 66, 701
DOI: 10.1021/acs.jcim.5c02045

Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras

Gerhard Hamilton, Sandra Stickler and Barbara Rath

CPD, 2023, 29, 1741
DOI: 10.2174/1381612829666230418114520

Recent advances in PROTAC-based antiviral and antibacterial therapeutics

Can Zhou, Shiwei Yang, Jun Wang, Wei Pan, Hongliang Yao, Gang Li and Minhong Niu

Bioorganic Chemistry, 2025, 160, 108437
DOI: 10.1016/j.bioorg.2025.108437

Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles

Vesna Vetma, Ilaria Puoti, Natalia K. Karolak, Sohini Chakraborti, Emelyne Diers, Enrico Girardi, Shakil Khan, Giorgia Kidd, Katrin G. Kropatsch, Ross Mclennan, Suzanne O’Connor, Matthias Samwer, Nicole Trainor, Claire Whitworth, Andre J. Wijaya, Jeff Y. F. Wong, David Zollman, William Farnaby, Johannes Popow, Alessio Ciulli, Peter Ettmayer and Kirsten McAulay

J. Am. Chem. Soc., 2025, 147, 41367
DOI: 10.1021/jacs.5c10354

DNA-Programmable Protein Degradation: Dynamic Control of Proteolysis-Targeting Chimera Activity via DNA Hybridization and Strand Displacement

Disha Kashyap, Shozeb Haider, Thomas A. Milne and Michael J. Booth

JACS Au, 2025, 5, 3799
DOI: 10.1021/jacsau.5c00422

Glutathione-dependent degradation of SMARCA2/4 for targeted lung cancer therapy with improved selectivity

Ming Ji, Dehao Yu, Xinmin Liu, Luo Wang, Dongli Zhang, Zhengduo Yang, Wanqiao Huang, Heli Fan, Lulu Wang and Huabing Sun

European Journal of Medicinal Chemistry, 2024, 277, 116751
DOI: 10.1016/j.ejmech.2024.116751

Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs

Rishi R. Shah, Elena De Vita, Preethi S. Sathyamurthi, Daniel Conole, Xinyue Zhang, Elliot Fellows, Eleanor R. Dickinson, Carlos M. Fleites, Markus A. Queisser, John D. Harling and Edward W. Tate

J. Med. Chem., 2024, 67, 4641
DOI: 10.1021/acs.jmedchem.3c02123

Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions

Akash Vikal, Rashmi Maurya, Brij Bihari Patel, Rajeev Sharma, Preeti Patel, Umesh K. Patil and Balak Das Kurmi

Drug Deliv. and Transl. Res., 2025, 15, 1801
DOI: 10.1007/s13346-024-01754-z

E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology

Iacovos N. Michaelides and Gavin W. Collie

J. Med. Chem., 2023, 66, 3173
DOI: 10.1021/acs.jmedchem.2c01882

Development of PROTACS degrading KRAS and SOS1

GERHARD HAMILTON, MARIE-THERESE EGGERSTORFER and SANDRA STICKLER

OR, 2024, 32, 1257
DOI: 10.32604/or.2024.051653

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

Rui Yao, Tianli Luo and Ming Wang

ChemBioChem, 2023, 24
DOI: 10.1002/cbic.202300413

Late-stage synthesis of heterobifunctional molecules for PROTAC applications via ruthenium-catalysed C‒H amidation

Daniele Antermite, Stig D. Friis, Johan R. Johansson, Okky Dwichandra Putra, Lutz Ackermann and Magnus J. Johansson

Nat Commun, 2023, 14
DOI: 10.1038/s41467-023-43789-9

Leveraging Targeted Protein Degradation for G Protein-Coupled Receptors: The Development of CCR2 Molecular Degraders

Khaled Essa, Natalia V. Ortiz Zacarías, Sascha Roth, Bo-Tao Xin, Sabine de Winter, Cas van der Horst, Bente Bleijs, Richard A. de Heiden, Rodanthi Voulgaraki, Elsa Neubert, Huib Ovaa, Erik H. J. Danen, Monique P. C. Mulder, Kevin Moreau, Daan van der Es and Laura H. Heitman

J. Med. Chem., 2025, 68, 26525
DOI: 10.1021/acs.jmedchem.5c02920

Histone Deacetylase 3‐Directed PROTACs Have Anti‐inflammatory Potential by Blocking Polarization of M0‐like into M1‐like Macrophages

Chunlong Zhao, Shipeng Chen, Deng Chen, Clàudia Río‐Bergé, Jianqiu Zhang, Petra E. Van Der Wouden, Toos Daemen and Frank J. Dekker

Angewandte Chemie, 2023, 135
DOI: 10.1002/ange.202310059

Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research

Meichen Pan, Zhongliang Fu, Hongwei Hou, Chunrong Yang and Jinghong Li

Small Methods, 2025, 9
DOI: 10.1002/smtd.202500402

Recent advances in developing targeted protein degraders

Binbin Cheng, Hongqiao Li, Xiaopeng Peng, Jianjun Chen, Chuxiao Shao and Zhihua Kong

European Journal of Medicinal Chemistry, 2025, 284, 117212
DOI: 10.1016/j.ejmech.2024.117212

VPS37A Activates the Autophagy-Lysosomal Pathway for TNFR1 Degradation and Induces NF-κB-Regulated Cell Death under Metabolic Stress in Colorectal Cancer

Chuncheng Liu, Xiaohan Liu, Ziqi Li, Yanruoxue Wei, Bangdong Liu, Peng Zhu, Yukun Liu and Ran Zhao

OR, 2025, 33, 2085
DOI: 10.32604/or.2025.065739

Proximity-Based Modalities for Biology and Medicine

Xingui Liu and Alessio Ciulli

ACS Cent. Sci., 2023, 9, 1269
DOI: 10.1021/acscentsci.3c00395

A Structural Investigation of the Interaction between a GC-376-Based Peptidomimetic PROTAC and Its Precursor with the Viral Main Protease of Coxsackievirus B3

Alessia De Santis, Deborah Grifagni, Andrea Orsetti, Elena Lenci, Antonio Rosato, Mariapina D’Onofrio, Andrea Trabocchi, Simone Ciofi-Baffoni, Francesca Cantini and Vito Calderone

Biomolecules, 2024, 14, 1260
DOI: 10.3390/biom14101260

Unveiling New Triazoloquinoxaline‐Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9

Martina Pierri, Guglielmo Bove, Erica Gazzillo, Ester Colarusso, Francesca Scala, Giacomo Pepe, Stefania Terracciano, Maria Giovanna Chini, Nicla Simonelli, Ines Bruno, Angela Nebbioso, Pietro Campiglia, Giuseppe Bifulco, Lucia Altucci, Nunzio Del Gaudio and Gianluigi Lauro

Chemistry A European J, 2025, 31
DOI: 10.1002/chem.202404218

Histone Deacetylase 3‐Directed PROTACs Have Anti‐inflammatory Potential by Blocking Polarization of M0‐like into M1‐like Macrophages

Chunlong Zhao, Shipeng Chen, Deng Chen, Clàudia Río‐Bergé, Jianqiu Zhang, Petra E. Van Der Wouden, Toos Daemen and Frank J. Dekker

Angew Chem Int Ed, 2023, 62
DOI: 10.1002/anie.202310059

Discovery of SMD-3236: A Potent, Highly Selective and Efficacious SMARCA2 Degrader for the Treatment of SMARC4-Deficient Human Cancers

Lin Yang, Wenbin Tu, Lingying Leng, Liyue Huang, Wei Jiang, Mi Wang, Yu Wang, Jennifer L. Meagher, Krishnapriya Chinnaswamy, Jeanne A. Stuckey, Meilin Wang, Bo Wen, Duxin Sun, Lalgudi Harikrishnan, Corey Strickland, Cory Rice, Peter Orth, Zhihua Sui and Shaomeng Wang

J. Med. Chem., 2025, 68, 1155
DOI: 10.1021/acs.jmedchem.4c01904

NMR-Based Fragment Screen of the von Hippel-Lindau Elongin C&B Complex

Kangsa Amporndanai, Jade M. Katinas, Ashima Chopra, Olumide Kayode, Anish K. Vadukoot, Alex G. Waterson and Stephen W. Fesik

ACS Med. Chem. Lett., 2025, 16, 1648
DOI: 10.1021/acsmedchemlett.5c00316

Drugit: crowd-sourcing molecular design of non-peptidic VHL binders

Thomas Scott, Christian Alan Paul Smethurst, Yvonne Westermaier, Moriz Mayer, Peter Greb, Roland Kousek, Tobias Biberger, Gerd Bader, Zuzana Jandova, Philipp S. Schmalhorst, Julian E. Fuchs, Aniket Magarkar, Christoph Hoenke, Thomas Gerstberger, Steven A. Combs, Richard Pape, Saksham Phul, Sandeepkumar Kothiwale, Andreas Bergner, Aleshin Dmitry Alekseevich, Walter Barmettler, Krzysztof Bogusz, Alexander Boykov, Andrew Cai, Jeffrey Michael Canfield, Andy M. Chen, Keith Clayton, Alan Roger Coral, Martin Dickel, Harald Feldmann, Lezhe Gao, Thomas J. George, Kevin M. Gildea, Gregory T. Hansen, Alyssa Joy Higgins, Renton Braden Mathew Innes, Bruno Kestemont, Allen Lubow, George Victor McIlvaine, Ian James McNaughton, Cédric Partinico, Vincent Pit, Alexa Sen, Michael Simon, Vera Simon, Robert Spearing, Bora Tastan, Stephen Vincent, Linda Wei, Jonathan Weinberg, Kevin D. Wells, Douglas Craig Wheeler, Ulas Yeginer, Scott J. Zaccanelli, Carlos Zambrano-Bukonja, Alex G. Waterson, Harald Weinstabl, Darryl B. McConnell, Jens Meiler, Jark Böttcher and Rocco Moretti

Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-58406-0

A novel proteolysis-targeting chimera strategy targeting multiple immune checkpoints containing ITIMs enhances antitumor immunity

Yue-Yuan Qiu, Zhao-Wei Wang, Lei He, Ge-Ge Shi, Zhao-Zhao Li, Shuang-Xin Ma, Duo Yu, Hai-Chen Du, Fei Xie, Cun Zhang, Ying-Qi Zhang, Meng Li and Wei-Na Li

Journal of Pharmaceutical Analysis, 2025, 101511
DOI: 10.1016/j.jpha.2025.101511

The 17th EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders

Alessio Ciulli, Suzanne O'Connor, Chun‐Wa Chung, Ingo V. Hartung, Andrea Testa, Danette L. Daniels and Laura H. Heitman

ChemMedChem, 2023, 18
DOI: 10.1002/cmdc.202300464

Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel–Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α Stabilizers

Lan Phuong Vu, Claudia J. Diehl, Ryan Casement, Adam G. Bond, Christian Steinebach, Nika Strašek, Aleša Bricelj, Andrej Perdih, Gregor Schnakenburg, Izidor Sosič, Alessio Ciulli and Michael Gütschow

J. Med. Chem., 2023, 66, 12776
DOI: 10.1021/acs.jmedchem.3c00434

Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability

Hao Wu, Jeremy Murray, Noriko Ishisoko, Alexandra Frommlet, Gauri Deshmukh, Antonio DiPasquale, Melinda M. Mulvihill, Donglu Zhang, John G. Quinn, Robert A. Blake, Wayne J. Fairbrother and Jakob Fuhrmann

J. Med. Chem., 2024, 67, 8585
DOI: 10.1021/acs.jmedchem.3c02203

Switchable and Stereospecific C-Glycosylation Strategy via Formal Functional Group Deletion

Xiaoshen Ma and Stephen J. Sujansky

J. Org. Chem., 2025, 90, 5259
DOI: 10.1021/acs.joc.5c00200

Beyond Binding Affinity: Detailed Profiling of Protein–Ligand Interactions with Time-Resolved FRET

Huan Liu, Fei Yang, Wenjing Li, Ling Ge, Mengjun Ma, Jingyue Xu, Chong Qin and Xue Qiu

Anal. Chem., 2026
DOI: 10.1021/acs.analchem.5c06619

Recent advances in targeting protein degradation for tumor immunotherapy

Shuai Li, Yushan Jin, Huanhuan Wu, Hong Yuan and Jingyuan Zhao

J Hematol Oncol, 2025, 19
DOI: 10.1186/s13045-025-01765-4

Structure-Based Design of “Head-to-Tail” Macrocyclic PROTACs

Chungen Li, Yihan Chen, Weixue Huang, Yudi Qiu, Shengjie Huang, Yang Zhou, Fengtao Zhou, Jian Xu, Xiaomei Ren, Jinwei Zhang, Zhen Wang, Ming Ding and Ke Ding

JACS Au, 2024, 4, 4866
DOI: 10.1021/jacsau.4c00831

Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment

Md Sadique Hussain, Liming Zhang, Amita Joshi Rana, Mudasir Maqbool, Sumel Ashique, Yumna Khan, Vikas Jakhmola, Ali Hanbashi, Wedad Mawkili and Gyas Khan

Future Medicinal Chemistry, 2025, 17, 1725
DOI: 10.1080/17568919.2025.2533113

Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9

Scott J. Hughes, Wojciech J. Stec, Colin T. R. Davies, David McGarry, Alicia Williams, Marta Carrara, Ivan Del Barco Barrantes, Rebecca Harris, Anna Tasegian, Dominic D. G. Owens, Alexander Fawcett, John Hellicar, Aleksandra Azevedo, Gregor P. Meier, Andrew C. Runcie, Liliana Greger, Martin O’Rourke, Ian Churcher, Martin Pass, Giles A. Brown, Alessio Ciulli, Louise K. Modis and Andrea Testa

Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-63594-w

Clues for glues: from serendipity to nature’s blueprints in degrader discovery

Zuzanna Kozicka

Essays in Biochemistry, 2025, 69, 379
DOI: 10.1042/EBC20253058

Therapeutic Targeting of Protein Lysine and Arginine Methyltransferases: Principles and Strategies for Inhibitor Design

Isaac Micallef and Byron Baron

IJMS, 2025, 26, 9038
DOI: 10.3390/ijms26189038

Pooled endogenous protein tagging and recruitment for systematic profiling of protein function

Yevgeniy V. Serebrenik, Deepak Mani, Timothé Maujean, George M. Burslem and Ophir Shalem

Cell Genomics, 2024, 4, 100651
DOI: 10.1016/j.xgen.2024.100651

Novel technologies are turning a dream into reality: conditionally replicating viruses as vaccines

Yan-Dong Tang, Changqing Yu and Xue-Hui Cai

Trends in Microbiology, 2024, 32, 292
DOI: 10.1016/j.tim.2023.09.002

Aptamer Proteolysis-Targeting Chimeras (PROTACs): A Novel Strategy to Combat Drug Resistance in Estrogen Receptor α-Positive Breast Cancer

Ying Feng, Zhilin Zhang, Haowei Zhang, Hui Guo, Chunyan Tan, Naihan Xu, Ying Tan and Yuyang Jiang

ACS Pharmacol. Transl. Sci., 2024, 7, 3945
DOI: 10.1021/acsptsci.4c00469

An overview of GPX4-targeting TPDs for cancer therapy

Xiaojuan Yang, Liqiang Wu and Shaohong Xu

Bioorganic & Medicinal Chemistry, 2025, 118, 118046
DOI: 10.1016/j.bmc.2024.118046

AMPK-activated BAP1 regulates pVHL stability and tumor-suppressive functions

Mei Li, Lei Huang, Jiayi Chen, Tangming Guan, Yalei Wen, Yingjie Zhu, Xiao Yang, Caishi Zhang, Xiuqing Ma, Rui Wan, Yuanqiao He, Yang Zhou, Yan Song, Haoxing Zhang and Tongzheng Liu

Cell Death Differ, 2025
DOI: 10.1038/s41418-025-01590-9

The cyclimids: Degron-inspired cereblon binders for targeted protein degradation

Saki Ichikawa, N. Connor Payne, Wenqing Xu, Chia-Fu Chang, Nandini Vallavoju, Spencer Frome, Hope A. Flaxman, Ralph Mazitschek and Christina M. Woo

Cell Chemical Biology, 2024, 31, 1162
DOI: 10.1016/j.chembiol.2024.01.003

Recent advances in targeted degradation in the RAS pathway

Zhiming Ge, Zisheng Fan, Wei He, Guizhen Zhou, Yidi Zhou, Mingyue Zheng and Sulin Zhang

Future Medicinal Chemistry, 2025, 17, 693
DOI: 10.1080/17568919.2025.2476387

A Lipid Prodrug Strategy Enhances Targeted Protein Degrader CNS Pharmacokinetics

Georges A. Leconte, Gillian E. Gadbois, Yadira Sepulveda, Ady Schwarz, Erin Chang, Raymond T. Suhandynata, Jeremiah D. Momper and Fleur M. Ferguson

J. Med. Chem., 2025, 68, 17339
DOI: 10.1021/acs.jmedchem.5c00866

A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs

Nikol A. Zografou-Barredo, Alex J. Hallatt, Jennyfer Goujon-Ricci and Céline Cano

Bioorganic & Medicinal Chemistry, 2023, 88-89, 117334
DOI: 10.1016/j.bmc.2023.117334

KRASG12D selective VHL-PROTAC with sparing KRASWT and other KRAS mutants

Eunhye Jeon, Chan Kim, Minjoo Ko, Taeyul K. Kim, Juhyeon Bae, Jae Won Oh, Kwang Pyo Kim, Han Sang Kim and Taebo Sim

European Journal of Medicinal Chemistry, 2025, 297, 117928
DOI: 10.1016/j.ejmech.2025.117928

Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression

Wei Wang, Youwei Li, Liu Tang, Yue Shi, Wensheng Li, Ling Zou, Liyuan Zhang, Yue Cheng, Zheng Yuan, Feng Zhu and Qiuhong Duan

Cancer Letters, 2024, 591, 216849
DOI: 10.1016/j.canlet.2024.216849

Clinical Translation of Targeted Protein Degraders

Nikki R. Kong and Lyn H. Jones

Clin Pharma and Therapeutics, 2023, 114, 558
DOI: 10.1002/cpt.2985

Design and characterization of a heterobifunctional degrader of KEAP1

Hao Chen, Nghi H. Nguyen, Charlene M. Magtoto, Simon A. Cobbold, Grace M. Bidgood, Lizeth G. Meza Guzman, Lachlan W. Richardson, Jason Corbin, Amanda E. Au, Bernhard C. Lechtenberg, Rebecca Feltham, Kate D. Sutherland, Christoph Grohmann, Sandra E. Nicholson and Brad E. Sleebs

Redox Biology, 2023, 59, 102552
DOI: 10.1016/j.redox.2022.102552

Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders

Nisha Setia, Haider Thaer Abdulhameed Almuqdadi and Mohammad Abid

European Journal of Medicinal Chemistry, 2024, 265, 116041
DOI: 10.1016/j.ejmech.2023.116041

The significant others of aurora kinase a in cancer: combination is the key

Kumar Nikhil and Kavita Shah

Biomark Res, 2024, 12
DOI: 10.1186/s40364-024-00651-4

Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics

Lisha Ou, Mekedlawit T. Setegne, Jeandele Elliot, Fangfang Shen and Laura M. K. Dassama

Chem. Rev., 2025, 125, 2120
DOI: 10.1021/acs.chemrev.4c00595

Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors

Chunlong Zhao, Jianqiu Zhang, Hangyu Zhou, Rita Setroikromo, Gerrit J. Poelarends and Frank J. Dekker

J. Med. Chem., 2024, 67, 14016
DOI: 10.1021/acs.jmedchem.4c00836

Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality

Yang Zhou, Shujing Xu, Nerea López-Carrobles, Dang Ding, Xinyong Liu, Luis Menéndez-Arias and Peng Zhan

Acta Materia Medica, 2023, 2
DOI: 10.15212/AMM-2023-0019

An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer

Lingping Kong, Fanlu Meng, Ping Zhou, Ruixin Ge, Xiaoshan Geng, Zhihao Yang, Guo Li, Linlin Zhang, Jing Wang, Jinfeng Ma, Cheng Dong, Jun Zhou, Sijin Wu, Diansheng Zhong and Songbo Xie

Science Bulletin, 2024, 69, 2122
DOI: 10.1016/j.scib.2024.05.017

VHL-Modified PROteolysis TArgeting Chimeras (PROTACs) as a Strategy to Evade Metabolic Degradation in In Vitro Applications

Beatrice Castellani, Michela Eleuteri, Stefano Di Bona, Gabriele Cruciani, Jenny Desantis and Laura Goracci

J. Med. Chem., 2023, 66, 13148
DOI: 10.1021/acs.jmedchem.3c01144

Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders

Zhenwu Li, Lalgudi S. Harikrishnan, Guozhang Xu, Debangshu Samanta, Jose C. Clemente, Lingying Leng, Wenbin Tu, Lin Yang, Liyue Huang, Mi Wang, Shaomeng Wang, Qiaolin Deng, Elham Behshad, Rakesh Nagilla, Peter Orth, Cory Rice, Corey Strickland, Helai P. Mohammad, E. Scott Priestley and Zhihua Sui

J. Med. Chem., 2025, 68, 1134
DOI: 10.1021/acs.jmedchem.4c01878

Targeted protein degradation as an antiviral approach

Antara Chakravarty and Priscilla L. Yang

Antiviral Research, 2023, 210, 105480
DOI: 10.1016/j.antiviral.2022.105480

Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy

Yanyu Jiang, Shuaishuai Ni, Biying Xiao and Lijun Jia

Acta Pharmaceutica Sinica B, 2023, 13, 4341
DOI: 10.1016/j.apsb.2023.07.019

Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development

Danishuddin, Mohammad Sarwar Jamal, Kyoung-Seob Song, Keun-Woo Lee, Jong-Joo Kim and Yeong-Min Park

Pharmaceuticals, 2023, 16, 1649
DOI: 10.3390/ph16121649

CD36-mediated endocytosis of proteolysis-targeting chimeras

Zhengyu Wang, Bo-Syong Pan, Rajesh Kumar Manne, Jungang Chen, Dongwen Lv, Minmin Wang, Phuc Tran, Tsigereda Weldemichael, Wei Yan, Hongfei Zhou, Gloria M. Martinez, Jingwei Shao, Che-Chia Hsu, Robert Hromas, Daohong Zhou, Zhiqiang Qin, Hui-Kuan Lin and Hong-Yu Li

Cell, 2025, 188, 3219
DOI: 10.1016/j.cell.2025.03.036

Development of Cathepsin B-Responsive GalNAc-PROTACs for Hepatocyte-Targeting Protein Degradation

Yunhua Peng, Tao Li, Donghua Liu, Wenxin Li, Yimeng Zhang, Ying Zhao, Xuehan Jiang, Yaqi Liang, Pengxiao Chen, Bohan Ma, Jing Liu and He Chen

J. Med. Chem., 2025
DOI: 10.1021/acs.jmedchem.5c02908

The value of protein allostery in rational anticancer drug design: an update

Ruth Nussinov and Hyunbum Jang

Expert Opinion on Drug Discovery, 2024, 19, 1071
DOI: 10.1080/17460441.2024.2384467

E3 ubiquitin ligases and their therapeutic potential in disease Management

Geet Madhukar, Md Azizul Haque, Shawez Khan, Jong-Joo Kim and Danishuddin

Biochemical Pharmacology, 2025, 236, 116875
DOI: 10.1016/j.bcp.2025.116875

Design of bifunctional molecules to accelerate post-translational modifications: achievements and challenges

Yuxuan Wang, Yanyi He, Qidong You and Lei Wang

Drug Discovery Today, 2024, 29, 104194
DOI: 10.1016/j.drudis.2024.104194

Design, synthesis and biological evaluation of KRASG12C-PROTACs

Xiaoyi Zhang, Tong Zhao, Minghao Sun, Pei Li, Mengzhen Lai, Lingfeng Xie, Jiaying Chen, Jian Ding, Hua Xie, Jinpei Zhou and Huibin Zhang

Bioorganic & Medicinal Chemistry, 2023, 78, 117153
DOI: 10.1016/j.bmc.2023.117153

Proteolysis-targeting chimera (PROTAC) nanomedicines toward cancer treatment: From synthesis to therapeutic delivery

Yilin Liu, Xiao Zhang, Xiaoyuan Chen and Fuwu Zhang

Biomaterials, 2026, 325, 123621
DOI: 10.1016/j.biomaterials.2025.123621

Mechanism of degrader-targeted protein ubiquitinability

Charlotte Crowe, Mark A. Nakasone, Sarah Chandler, Conner Craigon, Gajanan Sathe, Michael H. Tatham, Nikolai Makukhin, Ronald T. Hay and Alessio Ciulli

Sci. Adv., 2024, 10
DOI: 10.1126/sciadv.ado6492

Non-enzymatic protein targeting agents as a promising strategy for cancer treatment

Madison Ambrose, Jeremy Lee, Aleem Syed, Zamal Ahmed and Guang Peng

Front. Drug Discov., 2025, 5
DOI: 10.3389/fddsv.2025.1520734

Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV

Lydia S. Newton, Clara Gathmann, Sophie Ridewood, Robert J. Smith, Andre J. Wijaya, Thomas W. Hornsby, Kate L. Morling, Dara Annett, Riccardo Zenezini Chiozzi, Ann-Kathrin Reuschl, Morten L. Govasli, Ying Ying Tan, Lucy G. Thorne, Clare Jolly, Konstantinos Thalassinos, Alessio Ciulli, Greg J. Towers and David L. Selwood

Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-56317-8

Peptide-mediated inhibition of the transcriptional regulator Elongin BC induces apoptosis in cancer cells

Sabrina Fischer, Van Tuan Trinh, Clara Simon, Lisa M. Weber, Ignasi Forné, Andrea Nist, Gert Bange, Frank Abendroth, Thorsten Stiewe, Wieland Steinchen, Robert Liefke and Olalla Vázquez

Cell Chemical Biology, 2023, 30, 766
DOI: 10.1016/j.chembiol.2023.05.012

Hypoxia Increases Cardiac Proteasomal Activity and Differentially Modulates Cullin-RING E3 Ligases in the Naked Mole-Rat Heterocephalus glaber

W. Aline Ingelson-Filpula, Karen L. Kadamani, Mohammad Ojaghi, Matthew E. Pamenter and Kenneth B. Storey

Muscles, 2026, 5, 6
DOI: 10.3390/muscles5010006

Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity

Lin Yang, Wenbin Tu, Liyue Huang, Bukeyan Miao, Atsunori Kaneshige, Wei Jiang, Lingying Leng, Meilin Wang, Bo Wen, Duxin Sun and Shaomeng Wang

J. Med. Chem., 2023, 66, 10761
DOI: 10.1021/acs.jmedchem.3c00953

The rise of degrader drugs

Mingxing Teng and Nathanael S. Gray

Cell Chemical Biology, 2023, 30, 864
DOI: 10.1016/j.chembiol.2023.06.020

Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands

Hanqiao Xu, Takashi Kurohara, Nobumichi Ohoka, Genichiro Tsuji, Takao Inoue, Mikihiko Naito and Yosuke Demizu

Bioorganic & Medicinal Chemistry, 2023, 86, 117293
DOI: 10.1016/j.bmc.2023.117293

Covalent Bifunctional Molecules (CBMs): Achievements and Challenges

Yuting Xin, Fangsu Chen, Qidong You, Lei Wang and Qiuyue Zhang

Medicinal Research Reviews, 2026, 46, 176
DOI: 10.1002/med.70011

Bioorthogonal Chemistry: An Emerging Strategy for Targeted Protein Degradation

Pijun Zhou, Junda Li, Jinyi Xu, Yansong Ren and Shengtao Xu

Chemistry A European J, 2026, 32
DOI: 10.1002/chem.202502876

A Functional Assay for Mining Noninhibitory Enzyme Ligands from One Bead One Compound Libraries: Application to E3 Ubiquitin Ligases

Weijun Gui, Allison Goss and Thomas Kodadek

J. Am. Chem. Soc., 2025, 147, 31630
DOI: 10.1021/jacs.5c07307

A one-pot photocatalytic triazole-based linkerology for PROTACs

Jinhua Liu, Yaqi Deng, Jiabin Yin, Jian Ji, Cong Guan, Xuwen Chen, Xiang Wu, Tong Zhu and Shunying Liu

Cell Reports Physical Science, 2024, 5, 102139
DOI: 10.1016/j.xcrp.2024.102139

Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity

Jinmin Miao, Yunpeng Bai, Yiming Miao, Zihan Qu, Jiajun Dong, Ruo-Yu Zhang, Devesh Aggarwal, Brenson A. Jassim, Quyen Nguyen and Zhong-Yin Zhang

Molecules, 2023, 28, 6947
DOI: 10.3390/molecules28196947

Factors to Consider for Synthesis in 1536-Well Plates─An Amide Coupling Case Study for PROTAC Synthesis

Rebecca Stevens, Harry E. P. Palmer, Afjal H. Miah and Glenn A. Burley

J. Org. Chem., 2025, 90, 2192
DOI: 10.1021/acs.joc.4c02456

PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies

Ambati Himaja, Debojyoti Halder, Suvankar Banerjee, Swati Biswas, Nilanjan Adhikari and Balaram Ghosh

ChemMedChem, 2025, 20
DOI: 10.1002/cmdc.202500203

A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1

Antonin Tutter, Dennis Buckley, Andrei A. Golosov, Xiaolei Ma, Wei Shu, Daniel J. J. McKay, Veronique Darsigny, Dustin Dovala, Rohan Beckwith, Jonathan Solomon, Pasupuleti Rao, Lei Xu, Aleem Fazal, Andreas Lingel, Charles Wartchow, Jennifer S. Cobb, Amanda Hachey, Jennifer Tullai and Gregory A. Michaud

Nat Chem Biol, 2025, 21, 1688
DOI: 10.1038/s41589-025-01936-x

Proline Analogues in Drug Design: Current Trends and Future Prospects

Vladimir Kubyshkin and Pavel K. Mykhailiuk

J. Med. Chem., 2024, 67, 20022
DOI: 10.1021/acs.jmedchem.4c01987

Penfluridol inhibits melanoma growth and metastasis through enhancing von Hippel‒Lindau tumor suppressor‐mediated cancerous inhibitor of protein phosphatase 2A (CIP2A) degradation

Fuyan Xu, Jiao Li, Min Ai, Tingting Zhang, Yue Ming, Cong Li, Wenchen Pu, Yang Yang, Zhang Li, Yucheng Qi, Xiaomin Xu, Qingxiang Sun, Zhu Yuan, Yong Xia and Yong Peng

MedComm, 2024, 5
DOI: 10.1002/mco2.758

Targeted protein degradation in autoimmune diseases: from mechanisms to therapeutic breakthroughs

Yuxin Song, Boyang Zhou, Jiangang Long and Yunhua Peng

Journal of Autoimmunity, 2025, 156, 103475
DOI: 10.1016/j.jaut.2025.103475

Multitargeted protein degradation: Integrating small-molecule, biomacromolecular, and nano-PROTACs for paradigm shifts in drug discovery

Jinghua Yang, Yujing Zhang, Miao Zhang, Dongming Xing and Chao Wang

Materials Today Advances, 2025, 28, 100644
DOI: 10.1016/j.mtadv.2025.100644

Targeted Protein Degradation for Agricultural Applications: Rationale, Challenges, and Outlook

Denis Fourches, Joseph Pilotte, Brian E. Watts, Daniel J. Saltzberg and Robert M. Cicchillo

ACS Bio Med Chem Au, 2025, 5, 778
DOI: 10.1021/acsbiomedchemau.5c00111

Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation

Mohamed S. Nafie, Mohamed K. Diab, Asmaa S. A. Yassen, Amany M. Elshamy, Mohamed R. El Tohamy, Haytham O. Tawfik and Sherif Ashraf Fahmy

Drug Development Research, 2025, 86
DOI: 10.1002/ddr.70192

A long march for targeted protein degradation in the new era: expanding E3 ligases

Dazhao Mi, Anxin Huang, Jingfeng Song and Yihua Chen

Future Medicinal Chemistry, 2024, 16, 2189
DOI: 10.1080/17568919.2024.2409618

A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins

Ishaar P. Ganesan and Hiroaki Kiyokawa

Cancers, 2025, 17, 626
DOI: 10.3390/cancers17040626

HaloPROTAC3 treatment activates the unfolded protein response of the endoplasmic reticulum in nonengineered mammalian cell lines

Aleksandra S. Anisimova, G Elif Karagöz and Guillaume Thibault

MBoC, 2025, 36
DOI: 10.1091/mbc.E24-08-0342

PI5P4K inhibitors: promising opportunities and challenges

Koh Takeuchi, Lisa Nagase, Shun Kageyama, Hirotaka Kanoh, Masashi Oshima, Aki Ogawa‐Iio, Yoshiki Ikeda, Yuki Fujii, Sei Kondo, Natsuki Osaka, Takeshi Masuda, Tsukasa Ishihara, Yoshikazu Nakamura, Yoshihisa Hirota, Takehiko Sasaki, Toshiya Senda and Atsuo T. Sasaki

The FEBS Journal, 2025, 292, 4446
DOI: 10.1111/febs.17393

Unleashing the Power of Covalent Drugs for Protein Degradation

Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, Liang Shen, Hong‐Min Liu, Ying Liu, Yi‐Chao Zheng and Xing‐Jie Dai

Medicinal Research Reviews, 2025, 45, 1045
DOI: 10.1002/med.22101

The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma

Di Wu, Hongli Yin, Chun Yang, Zimu Zhang, Fang Fang, Jianwei Wang, Xiaolu Li, Yi Xie, Xiaohan Hu, Ran Zhuo, Yanling Chen, Juanjuan Yu, Tiandan Li, Gen Li and Jian Pan

BMC Cancer, 2024, 24
DOI: 10.1186/s12885-024-12691-y

Expanding the ligand spaces for E3 ligases for the design of protein degraders

Rahman Shah Zaib Saleem, Martin P. Schwalm and Stefan Knapp

Bioorganic & Medicinal Chemistry, 2024, 105, 117718
DOI: 10.1016/j.bmc.2024.117718

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death

Jonathan Mannion, Valentina Gifford, Benjamin Bellenie, Winnie Fernando, Laura Ramos Garcia, Rebecca Wilson, Sidonie Wicky John, Savita Udainiya, Emmanuel C. Patin, Crescens Tiu, Angel Smith, Maria Goicoechea, Andrew Craxton, Nathalia Moraes de Vasconcelos, Naomi Guppy, Kwai-Ming J. Cheung, Nicholas J. Cundy, Olivier Pierrat, Alfie Brennan, Theodoros I. Roumeliotis, Graeme Benstead-Hume, John Alexander, Gareth Muirhead, Scott Layzell, Wenxin Lyu, Victoria Roulstone, Mark Allen, Holly Baldock, Arnaud Legrand, Florian Gabel, Natalia Serrano-Aparicio, Chris Starling, Hongyan Guo, Jason Upton, Mads Gyrd-Hansen, Marion MacFarlane, Benedict Seddon, Florence Raynaud, Ioannis Roxanis, Kevin Harrington, Syed Haider, Jyoti S. Choudhary, Swen Hoelder, Tencho Tenev and Pascal Meier

Immunity, 2024, 57, 1514
DOI: 10.1016/j.immuni.2024.04.025

Small-Molecule Ferritin Degrader as a Pyroptosis Inducer

Yu Chen, Wen Li, Song Kwon, Yixin Wang, Zhaoting Li and Quanyin Hu

J. Am. Chem. Soc., 2023, 145, 9815
DOI: 10.1021/jacs.3c01852

Roles of E3 ubiquitin ligases and deubiquitinating enzymes in renal cell carcinoma

Minshu Jiang, Wenxia Si, Sien Huang, Sha Qu, Minghui Zhang and Yi Quan

Front. Oncol., 2026, 15
DOI: 10.3389/fonc.2025.1628710

Use of Direct-to-Biology Strategies for the Discovery of 2′-Deoxynucleoside 5′-Monophosphate N-Glycosidase (DNPH1) PROTACs

Niall A. Anderson, Bernard Barlaam, Argyrides Argyrou, Peter C. Astles, Hanna Bruss, Elaine B. Cadogan, Luca Carlino, Luz Alonso-Crisostomo, Gavin W. Collie, Alex J. Edwards, Anastasiia Gryniukova, James Hall, Kunzah Jamal, Joshua Kent, Linda Kitching, Christopher Kourra, Carolyn Lam, Alexander G. Milbradt, Jenni Nikkilä, Sarah Northall, Mark J. O’Connor, Jeroen Overman, Claudio Pathe, Wendy Savory, Daniel Slade, Jonathan A. Spencer, Darren Stead, Christopher J. Stubbs, Benjamin C. Whitehurst and Sabrina Winfield

J. Med. Chem., 2025, 68, 23421
DOI: 10.1021/acs.jmedchem.5c02337

CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications

Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, S. Renuka Jyothi, Irwanjot Kaur, Sachin Kumar, Naveen Sharma, G. V. Siva Prasad, Atreyi Pramanik and Haider Ali

Chem Biol Drug Des, 2024, 104
DOI: 10.1111/cbdd.70009

Targeted Degradation of Receptor-Interacting Protein Kinase 1 to Modulate the Necroptosis Pathway

Hiroyuki Inuzuka, Chao Qian, Yihang Qi, Yan Xiong, Chaoyu Wang, Zhen Wang, Dingpeng Zhang, Can Zhang, Jian Jin and Wenyi Wei

ACS Pharmacol. Transl. Sci., 2024, 7, 3518
DOI: 10.1021/acsptsci.4c00421

Expanding PROTACtable genome universe of E3 ligases

Yuan Liu, Jingwen Yang, Tianlu Wang, Mei Luo, Yamei Chen, Chengxuan Chen, Ze’ev Ronai, Yubin Zhou, Eytan Ruppin and Leng Han

Nat Commun, 2023, 14
DOI: 10.1038/s41467-023-42233-2

Current trends in theranostic applications of extracellular vesicles in cancer

Yazan Almasry, Fayrouz Mustafa, Mohammed Alfuwais, Sara AlNachef, Hager Mohamed, Nusaibah S. Gaber, Mohammed Imran Khan, Islam M. Saadeldin and Ahmed Yaqinuddin

Front. Oncol., 2025, 15
DOI: 10.3389/fonc.2025.1592006

Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy

Ru Si, Huanjie Zhu, Jin Wang, Qingqing Zhang, Yanchen Li, Xiaoyan Pan and Jie Zhang

Bioorganic Chemistry, 2023, 135, 106497
DOI: 10.1016/j.bioorg.2023.106497